Anazole is an antitumor medicine.
Pharmacological effect Anazole
Anazole is a strong and highly selective nonsteroidal aromatase inhibitor, an enzyme that, with the help of women, androstenedione and testosterone in tissues is converted to estrone and oestradiol, respectively. The reduction of circulating estradiol concentration in breast cancer patients has a therapeutic effect. In postmenopausal women, anastrozole at a daily dose of 1 mg causes a decrease in 80% of estradiol concentration.
Anazole has no progestative, androgenic and estrogenic activity. In daily doses up to 10 mg has no effect on the secretion of cortisol and aldosterone, therefore, when anastrozole is used, there is no need to replace corticosteroids.
The ATAC study included localized breast cancer and women received either anastrozole, tamoxifen or both for five years, followed by five years of follow-up. After more than 5 years, the group receiving anastrozole performed better than the tamoxifen group. The trial suggested that anastrozole is the preferred medical treatment for postmenopausal women with localized breast cancer, which is estrogen receptor (ER) positive. Another study showed that the risk of recurrence was reduced by 40%, but was associated with an increased risk of bone fractures. The study concluded that ER-positive patients benefited from the switch from tamoxifen to anastrozole in patients who received adjuvant tamoxifen therapy for 2 years. A more recent trial showed that anastrozole significantly reduced the incidence of breast cancer in postmenopausal women compared to placebo, and although estrogen deprivation-related side effects were observed, the researchers concluded that it was probably not related to the treatment. Lead author Jack Cuzick said, "This class of drugs is more effective than previous medications such as tamoxifen and, more importantly, has fewer side effects," adding that he thought there was enough evidence to support the offer of this drug. .